ZimVie Inc.

The conference will begin shortly. To raise your hand during Q&A, you can dial star 1 1. Good afternoon, and welcome to ZimV's third quarter 2022 earnings conference call. Currently, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Marissa Batch from Jill Martin Group Investor Relations for a few introductory comments.

Thank you all for joining today's call. Earlier today, Zimby released financial results for the quarter ended September 30, 2022. A copy of the press release is available on the company's website, Zimby.com, as well as on SEC.gov. Before we begin, I'd like to remind you that management will make comments during this call that include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. Please refer to the company's 2021 Form 10-K and subsequent SEC filings for a detailed discussion of these risks and uncertainties. Additionally, the discussion on this call will include certain non-GAAP financial measures. Reconciliations of these measures to the most directly comparable GAAP financial measures are included within the earnings release and or the investor deck issued today found on the investor relations section of the company's website, Zimbi.com. This conference call contains time-sensitive information and is accurate only as it's a live broadcast today, November 9, 2022. ZIMBIE disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. And with that, I will turn the call over to Vafa Jamali, President and Chief Executive Officer of ZIMBIE.

Good afternoon, and thank you all for joining us. I'm on the call today with Rich Eppenstall, our Chief Financial Officer. I'd like to kick off our call by providing an update on the operational progress we've made post-separation and then reviewing our financial performance for the quarter ended September 30, 2022. It remains early days for ZMV, and we're very pleased with the progress we've made on both the operational and organizational fronts in this short period of time. Despite a challenging macro environment and significant technical pressure to our shares as a function of post-spin trading dynamics, We remain confident in executing the long-range turnaround plan that we instituted earlier this year and see significant opportunity ahead. During our investment day in February, we identified three key priorities to building a strong foundation for the future of Zimby. First, we committed to establishing a world-class leadership team with the right talent across the organization to drive long-term growth. Today, our team is intact, bringing collective vision and experience to drive value for Zimby, its employees, and its patients. Second, we committed to optimizing systems and operations. To this end, we've successfully separated operations from our parent . We've also identified the greatest opportunities facing us to sustain operational excellence. We are now implementing work streams to capitalize on these opportunities. Areas of focus here include inventory management, facility consolidation, manufacturing excellence, and creating a nimble organizational structure. Our third priority is to create a portfolio of innovation to drive sustained growth across both our spine and dental portfolios. On this front, we've already launched several new and next generation products in the market, all in the short period of time since the spinoff. Last week, we launched our next generation TSX dental implant designed for immediate extraction and loading protocols, as well as placement predictability and primary stability in the soft and dense bone. We're hearing strong early feedback and engagement trends from the field. This launch comes off the heels of our T3 Pro and Encode Emergence launches in June, both of which have seen strong demand in the first few months of availability. These products offer an optimized implant experience for both dentists and patients, and we are excited to share that we'll have additional iterations for our product portfolio into 2023 and beyond. We also recently announced the launch of an exciting new innovation in our spine business, the Virage Navigation System, which allows the navigation of bone preparation instruments and polyaxial screws in the spine as compatible with commercially available navigation systems. This compatibility with third-party navigation systems supports our desire to be more active in the minimally invasive MIS procedures, where we believe innovation can help improve overall patient outcomes. We will continue to evolve our spine portfolio, innovating on and around our existing solutions, such as our differentiated motion preservation devices like our Movi-C cervical disc to improve physician experience and workflow while building on our long-standing track record of excellent patient outcomes. This includes exploring opportunities to expand our presence and compatibility in the ASC setting. Enabling technology remains an area of significant interest to us, and we see a real unmet need and substantial opportunity to drive pull-through of our current core spine portfolio and our differentiated motion preservation solutions. And we hope to provide additional updates here in the future. Turning to our performance in the third quarter, we delivered $213.3 million in total third-party net sales, declining 11% on a reported basis and 7% on a constant currency basis. Our results in the quarter were impacted to an extent by a stronger than typical summer seasonality in the July and August months, partially offset by a more favorable September volume. Rachel will provide greater detail on our quarterly performance shortly. Before I turn over the line, I want to reemphasize our steadfast dedication to innovating and executing across our business segments to drive future growth. Our mission is to advance clinical technology's foundational restoring daily life, and we will continue to bring innovative products to market to drive our top line and create shareholder value while addressing real patient needs in the dental and spine markets. I will now hand over the line to Rich Huffinsvall, our Chief Financial Officer.